As Vice-President for Radioligand Therapy, Celine leads the commercialization strategy of innovative targeted radioligand therapies in the field of nuclear medicine to help Canadian patients with advanced cancer. Celine joined Novartis in 2014 and, during her tenure, has been in a variety of commercial and leadership roles in various geographies including Europe, Asia, Middle East and North America. Prior to joining Novartis, Celine worked at AstraZeneca and Boston Consulting Group. Celine holds a master’s degree in business from ESSEC Business School in France. Celine has great passion for developing and leading high performing teams. She is energized by helping patients gain access to innovative therapies that will transform their lives.

Novartis Canada is leading the way in bringing an innovative targeted cancer treatment called radioligand therapy to Canadian patients. This approach uses radioactive particles attached to molecules that seek out and destroy cancer cells while minimizing harm to healthy tissue. For certain advanced cancers, such as prostate and neuroendocrine cancers, this therapy can offer significant benefits. The radioactive materials essential for these treatments are often sourced from the nuclear industry, underscoring the vital link between pharmaceutical innovation in cancer care and the supply of medical isotopes.